Showing results (591-600 of 1,030) with videos related to

Sort By:
Pageof 103
The Lancet. Respiratory Medicine|August 4, 2018
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trialsMargaret Neighbors, Christopher R Cabanski, Thirumalai R Ramalingam, et al.
The Lancet. Respiratory Medicine|August 14, 2018
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysisMichäel Duruisseaux, Anna Martínez-Cardús, Maria E Calleja-Cervantes, et al.
The Lancet. Respiratory Medicine|September 7, 2016
Lung cancer screening: latest developments and unanswered questionsCarlijn M van der Aalst, Kevin Ten Haaf, Harry J de Koning
The Lancet. Respiratory Medicine|June 12, 2017
Eosinophils in COPD: just another biomarker?Mona Bafadhel, Ian D Pavord, Richard E K Russell
The Lancet. Respiratory Medicine|May 25, 2018
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trialToby M Maher, Ellen M van der Aar, Olivier Van de Steen, et al.
The Lancet. Respiratory Medicine|April 8, 2018
Pulmonary sarcoidosisPaolo Spagnolo, Giulio Rossi, Rocco Trisolini, et al.
The Lancet. Respiratory Medicine|April 10, 2018
Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of lifeDinh S Bui, Caroline J Lodge, John A Burgess, et al.
The Lancet. Respiratory Medicine|June 13, 2018
Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing studyAmy Dressen, Alexander R Abbas, Christopher Cabanski, et al.
The Lancet. Respiratory Medicine|July 14, 2018
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort studyKathryn Schnippel, Norbert Ndjeka, Gary Maartens, et al.
The Lancet. Respiratory Medicine|September 13, 2016
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trialsNicola A Hanania, Phillip Korenblat, Kenneth R Chapman, et al.
Pageof 103